gefitinib has been researched along with cl 387785 in 11 studies
| Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (cl 387785) | Trials (cl 387785) | Recent Studies (post-2010) (cl 387785) |
|---|---|---|---|---|---|
| 5,231 | 566 | 2,919 | 34 | 0 | 14 |
| Protein | Taxonomy | gefitinib (IC50) | cl 387785 (IC50) |
|---|---|---|---|
| Proto-oncogene tyrosine-protein kinase Src | Gallus gallus (chicken) | 0.001 | |
| Epidermal growth factor receptor | Homo sapiens (human) | 0.0456 | |
| Receptor tyrosine-protein kinase erbB-2 | Homo sapiens (human) | 0.1952 | |
| Receptor tyrosine-protein kinase erbB-4 | Homo sapiens (human) | 0.012 | |
| Broad substrate specificity ATP-binding cassette transporter ABCG2 | Homo sapiens (human) | 0.2 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (72.73) | 29.6817 |
| 2010's | 3 (27.27) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hegedus, T; Kéri, G; Német, K; Orfi, L; Ozvegy-Laczka, C; Sarkadi, B; Schuetz, JD; Ujhelly, O; Váradi, A; Várady, G | 1 |
| Althaus, IW; Amato, DM; Bridges, AJ; Denny, WA; Elliott, WL; Ellis, PA; Fry, DW; Gonzales, AJ; Han, HK; Harvey, PJ; Klutchko, SR; Meade, MA; Nelson, JM; Pace, G; Roberts, BJ; Sherwood, V; Showalter, HD; Smaill, JB; Tran, TP; Winters, RT; Zhou, H | 1 |
| Da Settimo, F; La Motta, C; Martinelli, A; Nerini, E; Sartini, S; Tuccinardi, T | 1 |
| Anderton, MJ; Ashton, S; Bethel, PA; Box, M; Butterworth, S; Chorley, CG; Chuaqui, C; Colclough, N; Cross, DA; Dakin, LA; Debreczeni, JÉ; Eberlein, C; Finlay, MR; Grist, M; Hill, GB; Klinowska, TC; Lane, C; Martin, S; Orme, JP; Smith, P; Wang, F; Ward, RA; Waring, MJ | 1 |
| Abou El Ella, DA; Aly, RM; El-Motwally, AM; Ibrahim, DA | 1 |
| Desai, AA; Ratain, MJ | 1 |
| Halmos, B; Ji, H; Kobayashi, S; Meyerson, M; Tenen, DG; Wong, KK; Yuza, Y | 1 |
| Alvarez, JV; Bulmer, SE; Chen, TH; Feng, W; Frank, DA; Greulich, H; Hahn, WC; Jänne, PA; Meyerson, M; Sellers, WR; Zappaterra, M | 1 |
| Borrás, AM; Cantley, LC; Engelman, JA; Gale, CM; Heymach, JV; Jänne, PA; Jarrell, E; Johnson, BE; Lifshits, E; Mukohara, T; Naumov, GN; Sun, J; Tracy, S; Yeap, BY; Zejnullahu, K; Zhao, X | 1 |
| Golub, T; Halmos, B; Hetherington, CJ; Kobayashi, S; Lowell, AM; Meyerson, M; Monti, S; Shapiro, GI; Shimamura, T; Steidl, U; Tenen, DG | 1 |
| Choi, YJ; Chung, JH; Kim, CH; Kim, HR; Lee, CT; Lee, JC; Lee, JS; Rho, JK; Xu, X; Yoon, HI | 1 |
11 other study(ies) available for gefitinib and cl 387785
| Article | Year |
|---|---|
High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter.
Topics: Adenosine Triphosphatases; Animals; Cell Line; Cell Membrane; Drug Resistance, Multiple; Enzyme Inhibitors; HL-60 Cells; Humans; Insecta; Protein-Tyrosine Kinases | 2004 |
Tyrosine kinase inhibitors. 19. 6-Alkynamides of 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as irreversible inhibitors of the erbB family of tyrosine kinase receptors.
Topics: Alkynes; Amides; Aniline Compounds; Animals; Antineoplastic Agents; Cell Line; Dogs; ErbB Receptors; Haplorhini; Humans; Mice; Mice, Nude; Mice, SCID; Phosphorylation; Pyrimidines; Quinazolines; Rats; Receptor Protein-Tyrosine Kinases; Receptor, ErbB-2; Receptor, ErbB-4; Structure-Activity Relationship; Xenograft Model Antitumor Assays | 2006 |
Computational studies of epidermal growth factor receptor: docking reliability, three-dimensional quantitative structure-activity relationship analysis, and virtual screening studies.
Topics: Computational Biology; Computer Simulation; Databases, Protein; Drug Evaluation, Preclinical; ErbB Receptors; Humans; Protein Binding; Quantitative Structure-Activity Relationship | 2009 |
Structure- and reactivity-based development of covalent inhibitors of the activating and gatekeeper mutant forms of the epidermal growth factor receptor (EGFR).
Topics: ErbB Receptors; Models, Molecular; Mutation; Structure-Activity Relationship | 2013 |
Molecular design and synthesis of certain new quinoline derivatives having potential anticancer activity.
Topics: Antineoplastic Agents; Cell Proliferation; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; ErbB Receptors; Humans; MCF-7 Cells; Molecular Structure; Protein Kinase Inhibitors; Quinolines; Structure-Activity Relationship | 2015 |
EGFR pharmacogenomics: the story continues to mutate and evolve.
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Pharmacogenetics; Protein-Tyrosine Kinases; Quinazolines; Randomized Controlled Trials as Topic | 2005 |
An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Growth Processes; Cell Line, Tumor; DNA-Binding Proteins; Drug Interactions; ErbB Receptors; Gefitinib; Genes, erbB-1; Interleukin-3; Mice; Milk Proteins; Mutation; Phosphorylation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; STAT5 Transcription Factor; Trans-Activators | 2005 |
Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents; Cell Transformation, Neoplastic; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exons; Gefitinib; Genetic Therapy; Humans; Mice; Mice, Nude; Mutation; Neoplasms, Experimental; NIH 3T3 Cells; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Shc Signaling Adaptor Proteins; Src Homology 2 Domain-Containing, Transforming Protein 1; STAT3 Transcription Factor; Transfection; Tumor Stem Cell Assay | 2005 |
Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer.
Topics: Alleles; Animals; Apoptosis; Base Sequence; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Gene Amplification; Humans; Lung Neoplasms; Mice; Mutation, Missense; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-3; RNA Interference; Transfection; Xenograft Model Antitumor Assays | 2006 |
Transcriptional profiling identifies cyclin D1 as a critical downstream effector of mutant epidermal growth factor receptor signaling.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cyclin D; Cyclin-Dependent Kinases; Cyclins; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Flavonoids; Gefitinib; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mutant Proteins; Mutation, Missense; Oligonucleotide Array Sequence Analysis; Piperidines; Quinazolines; Signal Transduction; Transcription, Genetic; Transfection | 2006 |
Clinical and molecular evidences of epithelial to mesenchymal transition in acquired resistance to EGFR-TKIs.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Acinar Cell; Cell Line, Tumor; Cell Movement; Cell Shape; Deoxycytidine; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gemcitabine; Gene Expression Profiling; Humans; Lung Neoplasms; Middle Aged; Neoplasm Invasiveness; Pancreatic Neoplasms; Quinazolines; Sequence Deletion | 2011 |